Aurobindo Pharma Q3 Net Profit Jumps 8% on Europe, ARV Growth

• Aurobindo Pharma reported a net profit of ₹909.8 crore in Q3, up 7.5% year-on-year, despite a ₹65 crore labor code cost.
• Revenue grew 8.4% to ₹8,646 crore, driven by strong performance in Europe and the ARV segment.
• EBITDA increased 12.4% to ₹1,773.6 crore, with the margin expanding to 20.5%.
• The company maintained a strong net cash position of $251 million and generated $118 million in free cash flows.
• US formulations revenue rose 2.2% to ₹3,739 crore, while Europe formulations revenue surged 27.4% to ₹2,703 crore.